Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Giorgia BattipagliaAnnalisa RuggeriRadwan MassoudJean El CheikhMatthieu JestinAhmad AntarSyed Osman AhmedWalid RasheedMarwan ShaheenRamdane BelhocineEolia BrissotRemy DulerySandra EderFederica GiannottiFrancoise IsnardSimona LapusanMarie-Therese RubioAnne VekhoffMahmoud AljurfOllivier LegrandMohamad MohtyAli BazarbachiPublished in: Cancer (2017)
Sorafenib treatment after HSCT appears to be feasible and highly effective with dose individualization according to patient tolerability. Further analysis is needed to evaluate the immunomodulating role of sorafenib after HSCT. The data from the current support prospective controlled trials of sorafenib after HSCT. Cancer 2017;123:2867-74. © 2017 American Cancer Society.
Keyphrases
- tyrosine kinase
- allogeneic hematopoietic stem cell transplantation
- acute myeloid leukemia
- papillary thyroid
- epidermal growth factor receptor
- hematopoietic stem cell
- acute lymphoblastic leukemia
- squamous cell
- lymph node metastasis
- clinical trial
- big data
- electronic health record
- machine learning
- artificial intelligence